Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States.

Mark W Tenforde,Wesley H Self,Yuwei Zhu,Eric A Naioti,Manjusha Gaglani,Adit A Ginde, Kelly Jensen,H Keipp Talbot,Jonathan D Casey,Nicholas M Mohr,Anne Zepeski,Tresa McNeal,Shekhar Ghamande,Kevin W Gibbs,D Clark Files,David N Hager,Arber Shehu,Matthew E Prekker,Heidi L Erickson,Michelle N Gong,Amira Mohamed,Nicholas J Johnson,Vasisht Srinivasan,Jay S Steingrub,Ithan D Peltan,Samuel M Brown,Emily T Martin,Arnold S Monto,Akram Khan,Catherine L Hough,Laurence W Busse,Caitlin Ten Lohuis,Abhijit Duggal,Jennifer G Wilson,Nida Qadir,Steven Y Chang,Christopher Mallow,Carolina Rivas,Hilary M Babcock,Jennie H Kwon,Matthew C Exline,Mena M Botros,Adam S Lauring,Nathan I Shapiro,Natasha Halasa,James D Chappell,Carlos G Grijalva,Todd W Rice,Ian D Jones,William B Stubblefield,Adrienne Baughman,Kelsey N Womack,Jillian P Rhoads,Christopher J Lindsell,Kimberly W Hart,Caitlin Turbyfill,Samantha Olson,Nancy Murray,Katherine Adams,Manish M Patel

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2023）

引用 7|浏览57

暂无评分

摘要

In a period largely predating Omicron variant circulation, effectiveness of 2 mRNA doses against COVID-19-associated hospitalization was largely sustained through 9 months.

查看译文

关键词

COVID-19,duration of protection,mRNA,vaccine effectiveness,waning

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要